MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fnagi.2021.658226

Медицинская библиотека · Frontiers in aging neuroscience · 2021

Novel STMN2 Variant Linked to Amyotrophic Lateral Sclerosis Risk and Clinical Phenotype.

Theunissen Frances, Anderton Ryan S, Mastaglia Frank L, Flynn Loren L, Winter Samantha J, James Ian, Bedlack Richard, Hodgetts Stuart, Fletcher Sue, Wilton Steve D, Laing Nigel G, MacShane Mandi, Needham Merrilee, Saunders Ann, Mackay-Sim Alan, Melamed Ze'ev, Ravits John, Cleveland Don W, Akkari P Anthony

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVE

There is a critical need to establish genetic markers that explain the complex phenotypes and pathogenicity of ALS. This study identified a polymorphism in the Stathmin-2 gene and investigated its association with sporadic ALS (sALS) disease risk, age-of onset and survival duration.

METHODS

The candidate CA repeat was systematically analyzed using PCR, Sanger sequencing and high throughput capillary separation for genotyping. Stathmin-2 expression was investigated using RT-PCR in patient olfactory neurosphere-derived (ONS) cells and RNA sequencing in laser-captured spinal motor neurons.

RESULTS

In a case-control analysis of a combined North American sALS cohort (n = 321) and population control group (n = 332), long/long CA genotypes were significantly associated with disease risk (p = 0.042), and most strongly when one allele was a 24 CA repeat (p = 0.0023). In addition, longer CA allele length was associated with earlier age-of-onset (p = 0.039), and shorter survival duration in bulbar-onset cases (p = 0.006). In an Australian longitudinal sALS cohort (n = 67), ALS functional rating scale scores were significantly lower in carriers of the long/long genotype (p = 0.034). Stathmin-2 mRNA expression was reduced in sporadic patient ONS cells. Additionally, sALS patients and controls exhibited variable expression of Stathmin-2 mRNA according to CA genotype in laser-captured spinal motor neurons.

CONCLUSIONS

We report a novel non-coding CA repeat in Stathmin-2 which is associated with sALS disease risk and has disease modifying effects. The potential value of this variant as a disease marker and tool for cohort enrichment in clinical trials warrants further investigation.

Для цитирования: Theunissen Frances, Anderton Ryan S, Mastaglia Frank L, Flynn Loren L, Winter Samantha J, James Ian, Bedlack Richard, Hodgetts Stuart, Fletcher Sue, Wilton Steve D, Laing Nigel G, MacShane Mandi, Needham Merrilee, Saunders Ann, Mackay-Sim Alan, Melamed Ze'ev, Ravits John, Cleveland Don W, Akkari P Anthony. Novel STMN2 Variant Linked to Amyotrophic Lateral Sclerosis Risk and Clinical Phenotype.. Frontiers in aging neuroscience. 2021. DOI: 10.3389/fnagi.2021.658226.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.